Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferric hydroxide polymaltose complex (also known as iron polymaltose complex or IPC) is an oral iron supplement used for the prevention and treatment of iron deficiency and iron deficiency anemia. It consists of a stable macromolecular complex of polynuclear iron(III) hydroxide cores surrounded and stabilized by a polymaltose (partially hydrolyzed dextrin) shell. Unlike traditional ferrous salts (such as ferrous sulfate), which release free iron ions rapidly in the gastrointestinal tract and can cause significant oxidative stress and mucosal irritation, the non-ionic complex of ferric hydroxide polymaltose complex allows for controlled, active absorption of iron in the small intestine (primarily the duodenum and jejunum). This mechanism mimics physiological iron absorption, resulting in superior gastrointestinal tolerability, fewer side effects (such as constipation, nausea, and abdominal pain), and a lower risk of accidental toxicity or iron overload. Once absorbed, the iron is transported via transferrin to the bone marrow for hemoglobin synthesis or stored in the liver and spleen as ferritin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferric hydroxide polymaltose complex.